Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus: Clinical trial
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus ...
Oct 21, 2023
0
0